Oligonucleotide CDMO Market Set to Reach $11.14 Billion by 2031 The oligonucleotide contract development and manufacturing organization (CDMO) market is
Category: Antisense Oligonucleotides
Antisense Oligonucleotides Offer Hope for Rare Neurodevelopmental Disorder
Scientists at St. Jude Children’s Research Hospital have made significant strides in reversing the effects of HNRNPH2 related neurodevelopmental disorder
Unraveling the Genetic Link Between ALS and FTD
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) may seem unrelated at first glance, yet groundbreaking research has uncovered a
Advancements in Nanocarriers for Targeted Delivery of Peptides and Oligonucleotides
Nanocarriers are revolutionizing the delivery of sensitive therapeutic agents, particularly peptides and oligonucleotides. By encapsulating these fragile